Immunotherapy, A2aR, PDR001, NIR178, NSCLC, solid tumors
Showing 1 - 25 of >10,000
NSCLC (NSCLC), Triple Negative Breast Cancer (TNBC), Pancreatic Ductal Adenocarcinoma (PDAC) Trial in Worldwide (NZV930, PDR001,
Terminated
- Non-small Cell Lung Cancer (NSCLC)
- +6 more
- NZV930
- +2 more
-
Tampa, Florida
- +9 more
Nov 2, 2022
NSCLC (NSCLC) Trial in Tampa (PBF-509_80 mg, PBF-509_160 mg, PBF-509_320 mg)
Completed
- Non-small Cell Lung Cancer (NSCLC)
- PBF-509_80 mg
- +8 more
-
Tampa, FloridaH.Lee Moffitt Cancer center
Jan 3, 2022
Renal Cell Carcinoma, Melanoma, Solid Tumor Trial in Pittsburgh (Phase Ib ARRY-614 + nivolumab, Phase Ib ARRY-614 +
Recruiting
- Renal Cell Carcinoma
- +4 more
- Phase Ib ARRY-614 + nivolumab
- +4 more
-
Pittsburgh, PennsylvaniaUPMC Hillman Cancer Center
Jan 9, 2022
Minimal Residual Disease, KRAS G12D, KRAS G12R Trial in United States (ELI-002 2P)
Recruiting
- Minimal Residual Disease
- +11 more
- ELI-002 2P
-
Duarte, California
- +10 more
Jan 18, 2023
NSCLC Trial in Washington, Hackensack, Neptune (Nivolumab, Ipilimumab, Carboplatin)
Not yet recruiting
- Carcinoma, Non-Small-Cell Lung
- Nivolumab
- +4 more
-
Washington, District of Columbia
- +2 more
Jan 27, 2023
Triple Negative Breast Cancer, Pancreatic Carcinoma, Melanoma Trial in Worldwide (MCS110, PDR001)
Completed
- Triple Negative Breast Cancer
- +3 more
-
Boston, Massachusetts
- +19 more
Jul 12, 2021
Metastatic Solid Tumor, Colon Cancer, Nonsmall Cell Lung Cancer Trial in France, Switzerland, United Kingdom (1.0% IP-001 for
Recruiting
- Metastatic Solid Tumor
- +3 more
- 1.0% IP-001 for Injection
-
Bordeaux, France
- +9 more
Jan 26, 2023
Carcinoma, Renal Cell, NSCLC Trial in Belgium, France (Live Bacterial Product - Akkermansia muciniphila)
Recruiting
- Carcinoma, Renal Cell
- Carcinoma, Non-Small-Cell Lung
- Live Bacterial Product - Akkermansia muciniphila
-
Mons, Belgium
- +3 more
May 9, 2023
Neoadjuvant Immunotherapy in Advanced NSCLC
Not yet recruiting
- Lung Cancer, Non-small Cell
- Immunotherapy
-
San Francisco, CaliforniaPower Life Sciences
Jan 21, 2022
Metastatic NSCLC Trial in Worldwide (Pembrolizumab, Lenvatinib, Docetaxel)
Active, not recruiting
- Metastatic Non-Small Cell Lung Cancer
- Pembrolizumab
- +2 more
-
Bakersfield, California
- +142 more
Sep 1, 2022
Non Squamous Non Small Cell Lung Cancer, EGFR Positive NSCLC Trial (Toripalimab plus Chemotherapy)
Not yet recruiting
- Non Squamous Non Small Cell Lung Cancer
- EGFR Positive Non-small Cell Lung Cancer
- Toripalimab plus Chemotherapy
- (no location specified)
Jul 28, 2023
Gynecologic Cancer, Colorectal Cancer, Pancreatic Cancer Trial in Houston (Neoantigen specific TCR-T cell drug product,
Recruiting
- Gynecologic Cancer
- +11 more
- Neoantigen specific TCR-T cell drug product
- Aldesleukin (IL-2)
-
Houston, TexasMD Anderson Cancer Center
Jul 27, 2022
Combined Statin and PD-1/PD-L1 Inhibitors in Treating Non-small
Recruiting
- Lung Cancer
-
Yiwu, Zhejiang, ChinaThe Fourth Affiliated Hospital of Zhejiang University
Dec 16, 2022
Metastatic Colorectal Cancer Trial in Sutton (PDR001, bevacizumab, mFOLFOX6)
Terminated
- Metastatic Colorectal Cancer
- PDR001
- +2 more
-
Sutton, Surrey, United KingdomNovartis Investigative Site
Oct 7, 2021
Non Small Cell Lung Cancer Recurrent Trial (Toripalimab, Anlotinib and Chemotherapy)
Not yet recruiting
- Non Small Cell Lung Cancer Recurrent
- Toripalimab, Anlotinib and Chemotherapy
- (no location specified)
Apr 24, 2023
Locally Advanced/Metastatic Solid Tumors Trial in United States (BJ-001, Pembrolizumab)
Recruiting
- Locally Advanced/Metastatic Solid Tumors
-
Saint Louis, Missouri
- +4 more
Jun 5, 2022
Solid Tumor, ARID1A Gene Mutation Trial in Greenville (Tazemetostat)
Suspended
- Solid Tumor
- ARID1A Gene Mutation
-
Greenville, South CarolinaPrisma Health Cancer Institute
Jan 10, 2023
MSI-H Colorectal Cancer, Melanoma, Anal Carcinoma Trial in Spain (Spartalizumab)
Active, not recruiting
- MSI-H Colorectal Cancer
- +30 more
-
Badalona, Barcelona, Spain
- +9 more
Oct 24, 2022